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In the previous issue of Critical Care,  Hamzaoui and 
colleagues present an observational study on the haemo-
dynamic eﬀ  ects of norepinephrine in septic patients with 
life-threatening hypotension [1]. Within 6 hours of 
admission to the intensive care unit, a threshold mean 
arterial pressure (MAP) ≤65 mmHg was selected to 
commence an infusion of norepinephrine, regardless of 
the degree of prior volume resuscitation. Measurements 
of cardiac index and derived indices of preload (end-
diastolic global volume index) and stroke volume varia-
tion were made at baseline and following augmentation 
of MAP with norepinephrine. Th   e patients were further 
categorised according to baseline left ventricular ejection 
fraction and whether they were able to achieve the target 
MAP. Th   e investigators found that norepinephrine 
signiﬁ   cantly increased MAP to a median value of 
75  mmHg, which was associated with signiﬁ  cant 
increases in cardiac output and indices of stroke volume 
and preload. Th  is eﬀ  ect was consistent independent of 
baseline left ventricular ejection fraction – apart from 
those patients with left ventricular ejection fraction 
<45%, who attained MAP >75  mmHg. Th  e authors 
concluded that the early administration of nor  epi-
nephrine directed at achieving a target systemic per-
fusion pressure was achievable through parallel increases 
in cardiac output and preload.
Although Hamzaoui and colleagues’ study is obser-
vational and single-centred in a relatively small popu-
lation of septic patients using derived indices from pulse 
contour analysis to quantify changes in preload and 
contractility [1], the results are consistent with physio-
logical models that deﬁ   ne the protean haemodynamic 
eﬀ   ects of endogenous catecholamines, speciﬁ  cally 
norepinephrine, under homeostatic and pathological 
conditions.
Norepinephrine is the predominant endogenous 
sympathetic amine acting in all populations of adreno-
receptors [2]. Th   ere is a common misperception that this 
amine is predominantly an α-agonist. Norepinephrine 
exhibits sympathetic activity over an expanding popu-
lation of adrenoreceptors on the circulation (α1A and α1B, 
α2A, α2B and α2C, β1, β2 and β3), acting centrally on the 
myo  cardium, on the arterial (conduit) circulation and on 
the venous (capacitance) circulation [3]. Haemodynamic 
function at any point in time represents the balance 
between the two circulations, so that changes in one are 
represented by compensatory changes in the other [4,5].
Under pathological conditions such as septic shock, 
qualitative and quantitative changes in cardiac function 
and vascular responsiveness result in unpredictable 
cardio  vascular responses between and within individuals, 
initially as a compensated high output or vasodilated 
state to a decompensated low output or vasoplegic state. 
Teleologically, this represents exhaustion of endogenous 
neurohumoral responses induced by pathological pro-
cesses or an overwhelmed host response. In this context, 
the use of exogenous infusions of catecholamines, such 
as norepinephrine or epinephrine, should be seen as 
neurohormonal augmentation therapy to defend decom-
pensating haemodynamic function rather than as a 
rescue therapy to treat shock [6].
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© 2010 BioMed Central LtdTh   is understanding is somewhat at variance to 
traditional clinical practice, supported by current guide-
lines that recommend haemodynamic resuscitation 
follows a step-wise approach – initial ﬂ  uid  loading, 
followed by the use of an inotrope to improve cardiac 
output, followed by a vasopressor to squeeze the 
circulation to augment the perfusion pressure [7].
Th  ree recently published randomised controlled trials 
comparing the eﬀ  ects of catecholamines in severe sepsis 
have demonstrated equivalence in haemodynamic 
responses without adverse eﬀ  ects on organ function or 
mortality [8-10]. Of the three catecholamines studied, 
norepinephrine was associated with the lowest incidence 
of drug-speciﬁ  c side eﬀ  ects compared with epinephrine 
(hyperlactataemia and hyperglycaemia) and dopamine 
(arrhythmias). On the basis of these studies and a recent 
commentary [11], norepinephrine appears to be the 
initial agent of choice. Furthermore, these trials represent 
a perceptible change in clinical practice to preferentially 
use catecholamines early in resuscitation to defend MAP 
as the principal haemodynamic endpoint, although it is 
acknowledged that there is little evidence or agreement 
on an optimal perfusion pressure in septic shock [12].
Th  e justiﬁ  cation for selecting MAP is based on prag-
matic reasons – MAP is easy and accurate to measure – 
as well as it being an aggregate index of organ perfusion 
pressure. However, as there is little direct relationship 
between perfusion pressure and venous return, which 
remains diﬃ   cult to measure under clinical conditions, 
clinicians rely on the assumption that parallel changes in 
the arterial and venous circulations will occur.
Th  e use of norepinephrine as a neurohormonal aug-
men  tation therapy by Hamzaoui and colleagues demon-
strated inotropic and vasopressor responses in a hetero-
geneous population of patients with severe sepsis using 
current monitoring techniques [1]. Th   ese data are 
consistent with established biological and basic science 
evidence, and provide addi  tional strength to the 
argument for viewing nor  epi  nephrine as a neurohormone 
rather than as a vasopressor and to recommend its early 
use as the ﬁ  rst-line agent for life-threatening hypotension.
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